A Practical Approach to Insulin Therapy in
Type 2 Diabetes Mellitus

Daniel Einhorn, MD

Module 1: Advantages and disadvantages of insulin

Module 2: Insulin options and regimens

Module 3: Glucose monitoring

Module 4: Diabetic complications

Introduction

Daniel Einhorn, MD, Medical Director, Scripps Whittier Institute for Diabetes, provides a basic overview of insulin options and regimens in the management of type 2 diabetes mellitus. Dr. Einhorn will also review glucose monitoring and complications of type 2 diabetes.

Intended Audience

This continuing medical education program is intended for primary care physicians and other healthcare professionals who manage patients with type 2 diabetes.

Educational Objectives

After completing this activity, participants should be better able to:

Describe the advantages and disadvantages of insulin therapy
Tailor the use of insulin to individual patients based on kinetic profiles of different insulin preparations
Relate to the patient the need for daily glucose monitoring and how much monitoring is enough
Review the clinical and life style measures needed to prevent or reduce the risk of micro- and macrovascular complications of type 2 diabetes

Information on CME credit

The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Medical Association designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nonphysicians may receive a certificate of participation for completing this activity.

Instructions for CME credit

This online enduring material is presented as an audio webcast with attendant slide presentation. To receive credit, please view all of the presentations of this CME activity and evaluate the content presented. Complete both the pre- and post-test and activity evaluation.

The estimated time to complete this activity, including pre-test, review of the materials, and self-assessment and evaluation is 1.0 hour.

Advisory Board

Stanley H. Hsia, MD, FRCPC, FACE, Planning Committee, Content Reviewer
Program Director, Endocrinology, Metabolism & Molecular Medicine
Assistant Professor of Medicine, Division of Endocrinology and Metabolism
Charles R. Drew University of Medicine and Science
UCLA School of Medicine
Los Angeles, CA

Daniel Einhorn, MD, FACP, FACE, Author and Presenter
Medical Director, Scripps Whittier Institute for Diabetes
Clinical Professor of Medicine, UCSD
President, Diabetes and Endocrine Associates
La Jolla, CA

Martin S. Lipsky, MD, Planning Commtitee, Content Reviewer
Dean, University of Illinois College of Medicine at Rockford
Professor, Department of Family and Community Medicine
Rockford, IL

Col. Robert A. Vigersky, MD, Planning Committee, Content Reviewer
Director, Diabetes Institute
Walter Reed Health Care System
Clinical Associate Professor, Department of Medicine
Georgetown University School of Medicine
Washington, DC

R. Mark Evans, PhD, Planning Commtitee, Content Reviewer
Director, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Kristi Eidsvoog, PhD, Planning Committee, Content Reviewer
Content Manager
MedEd Architects, LLC
Chicago, IL

Patti Fitzgerald, Planning Committee, Content Reviewer
Manager, Product Development, Healthcare Education Products and Standards
American Medical Association
Chicago, IL

Disclosure Policy

In order to assure the highest quality of CME programming, and to comply with the ACCME Standards for Commercial Support, the AMA requires that all faculty and planning committee members disclose relevant financial relationships with any commercial or proprietary entity producing health care goods or services relevant to the content being presented. We therefore obtain a completed disclosure and attestation form to inform the participant of any pertinent relationships disclosed, provided here.

These materials have been peer-reviewed by the members of the CME Advisory Board and the AMA Editorial Board to ensure the continued scientific accuracy and medical relevance of information presented and its independence from commercial bias. The AMA has control over all final

Dr. Einhorn: Research Grants, Aventis, Allergan, Lilly, Medtronic, Pfizer, sanofi-aventis; Consultant, Amylin, Lilly, MannKind, Medtronic, Takeda; Speaker’s Bureau, Amylin, Merck, sanofi-aventis, Takeda; Significant Shareholder, MannKind.

Dr. Hsia: Consultant, Merck

Dr. Lipsky: Nothing relevant to disclose

Dr. Vigersky: Research Grants, DexCom, NovoNordisk, Pfizer, Roche; Stockholder, Merck

Dr. Eidsvoog: Nothing relevant to disclose

Dr. Evans: Nothing relevant to disclose

Ms. Fitzgerald: Nothing relevant to disclose

Acknowledgement of Support

This CME publication was supported through an independent education grant from Takeda Pharmaceuticals and produced in accordance with the AMA Standards for Industry-Supported Multimedia Continuing Medical Education and Other Communications.